Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 683

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on Oral PHA-022121 for Preventing Angioedema Attacks in Patients with Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide

Neoplasm malignant

Not recruiting

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Small cell lung cancer extensive stage

Not recruiting

Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

HER2 positive breast cancer

Not recruiting

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

Neoplasm

Not recruiting

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Hypertrophic cardiomyopathy

Not recruiting

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986435

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid

Psoriatic arthropathy

Not recruiting

Study on Upadacitinib for Pain Management in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

PIK3CA related overgrowth spectrum

Not recruiting

Study on the Long-Term Safety of Alpelisib for Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.